The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

SGLT2 Inhibitor Therapy in Heart Failure

SGLT2 inhibitor therapy that improves survival and reduces hospitalizations in HFrEF and HFpEF.

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Kardiyoloji department. Book Appointment →

What is SGLT2 Inhibitor Therapy in Heart Failure?

SGLT2 inhibitors (dapagliflozin, empagliflozin) were originally developed for type 2 diabetes but have become cornerstones of heart failure therapy following large clinical trials. They significantly reduce cardiovascular death and hospitalization in both HFrEF and HFpEF.

These drugs inhibit glucose reabsorption in the proximal renal tubule, increasing urinary glucose and sodium excretion. This diuretic-like effect reduces cardiac preload, suppresses neurohormonal activation and favorably affects myocardial metabolism.

Guidelines now include SGLT2 inhibitors with a class 1 recommendation in addition to standard therapy (ARNI/ACEI-ARB, beta-blocker, MRA) for symptomatic HFrEF.

Symptoms

Dyspnea
Foot and leg edema
Fatigue
Weight gain
Orthopnea
Paroxysmal nocturnal dyspnea
Exercise intolerance

Risk Factors

HFrEF (EF ≤ 40%)
HFpEF (EF ≥ 50%)
Diabetes mellitus
Chronic kidney disease
Prior cardiac event
High NT-proBNP
History of hospitalization

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New or worsening heart failure signs
  • Weight gain and edema
  • Worsening dyspnea
  • Evaluation before starting SGLT2i
  • Urinary tract infection or dehydration
  • Signs of diabetic ketoacidosis

Treatment Methods

01
Dapagliflozin or empagliflozin
02
Combination with ARNI
03
Beta-blocker titration
04
Combination with MRA
05
Diuretic therapy
06
Monitoring of renal function
07
Monitoring for urinary infection

Which Department to Visit?

You can visit our Kardiyoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Kardiyoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Hypertension (High Blood Pressure)

Kardiyoloji

Hypertension is a condition in which blood pressure readings remain above 140/90 mmHg; early treatment helps prevent serious complications.

Coronary Artery Disease

Kardiyoloji

Narrowing of the coronary arteries due to atherosclerosis can cause chest pain (angina) and heart attack.

Heart Failure

Kardiyoloji

Heart failure is a chronic cardiac condition characterized by shortness of breath, leg swelling, and fatigue.

Heart Attack (Myocardial Infarction)

Kardiyoloji

A heart attack is a medical emergency; because heart muscle is lost by the minute, immediate intervention saves lives.

Atrial Fibrillation

Kardiyoloji

Atrial fibrillation is a common arrhythmia characterized by an irregular heartbeat and increased risk of stroke.

Heart Palpitations

Kardiyoloji

Palpitations are usually due to benign causes, but underlying cardiac rhythm disorders must be ruled out.

Heart Valve Diseases

Kardiyoloji

Valve stenosis or regurgitation increases the workload of the heart and, over time, can lead to heart failure.

Aortic Aneurysm

Kardiyoloji

Aortic aneurysms are often silent; early diagnosis allows treatment before rupture (a life-threatening tear).

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.